Sign in
Taking people in United StatesPhase 4

A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects

Key facts

Who runs it
Berkeley Eye Center
Where
Houston and Plymouth Meeting, United StatesSee the 2 sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
320 people, planned
Started
17 Mar 2025
Expected to end
Apr 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Clareon PanOptix
  • Clareon PanOptix PRO
  • Mix-and-Match PanOptix/Vivity
Record updated
30 September 2026

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Adult cataract patients aged 40 years and older scheduled for age related cataract surgery in both eyes
  • Ability to understand and sign an ethics committee-approved informed consent form
  • Willingness and ability to attend all scheduled study visits as required by the protocol
  • Postoperative potential visual acuity of 20/25 or better in each eye, as determined by the investigator
  • Preoperative corneal astigmatism that can be corrected with a T3 or T4 toric IOL, or with a spherical IOL and LRIs or AKs resulting in a predicted postoperative astigmatism of less than 0.5 diopters (D)
  • Ability to understand and complete questionnaires

Who cannot take part

  • Prior ocular surgery (except for uncomplicated cataract surgery in the fellow eye)
  • Ocular conditions that could confound study results, including moderate to severe corneal pathology, irregular astigmatism, moderate to severe dry eye, preexisting retinal diseases such as macular degeneration or diabetic retinopathy
  • Systemic conditions that may affect healing or visual outcomes (e.g., uncontrolled diabetes mellitus, certain autoimmune disorders)
  • Any active ocular infection or inflammation (except for routine post-operative inflammation in the fellow eye)
  • Psychiatric or cognitive disorders that may impair the ability to comply with study procedures or provide accurate self-assessments
  • Women who are pregnant, planning to become pregnant during the study, or breastfeeding
  • Any form of confirmed glaucomatous damage (ie, mild, moderate, or severe glaucoma)
  • Participation in another clinical study that could interfere with the results
  • Subjects with nystagmus, strabismus, zonular laxity or dehiscence, and pseudoexfoliation
  • Participants desiring monovision
  • RMS total higher-order aberrations (HOAs) >0.70 µm or coma >0.40 µm as measured by tomography or topography with a 4 mm pupil setting

This trial is currently available in United States.

  • Berkeley Eye CenterHouston, United StatesContact: Tetiana HuffTaking people
  • Shafer Vision InstitutePlymouth Meeting, United StatesContact: Ailinn DunnTaking people

About the trial

What the trial wants to find out

Prospective, randomized, multicenter, multi-arm, subject and vision-assessor-masked, two stage study with Stage 1 as a three-arm initial enrollment period, followed by Stage 2 as a head-to-head study refined based on the Stage 1 data.

The 3 groups in the trial

  • Bilateral Clareon PanOptix IOL implantationExisting treatment, for comparison

    Treatment: Clareon PanOptix

  • Bilateral Clareon PanOptix Pro IOL implantationTreatment being tested

    Treatment: Clareon PanOptix PRO

  • Clareon PanOptix Pro in the non-dominant eye and Clareon Vivity in the dominant eyeTreatment being tested

    Treatment: Mix-and-Match PanOptix/Vivity

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
30 September 2026